Despite the availability of therapies directed for hormone-receptor(HR)-positive, human epidermal growth factor receptor 2 (HER2)–negative (HR+/HER2-) advanced breast cancer, many patients eventually develop treatment resistance. 1 Given the role in cell-cycle progression, cyclin-dependent kinases 4 and 6 (CDK4/6) have emerged as important targets and have shown improved outcomes in patients with advanced breast cancer. The inhibitor of these kinases, Ribociclib, a selective small-molecule inhibitor of CDK4/6, approved for the treatment HR+/HER2- advanced breast cancer has shown significantly better progression-free survival outcomes in patients as compared with standard therapy. 2 Reference: Matutino , et al.,. Current Oncology.
2018;25:131. Slamon D, et al., New England Journal of Medicine. 2020;382(2):514-524. Novartis and Docplexus have organized an interactive webinar on 27 th…
